US govt outlines plan to provide free COVID-19 vaccines

Market recovery is contingent on a COVID-19 vaccine before year-end

The deluge of selling that nearly pushed the S&P 500 into a correction may be over as investors look ahead to a further reopening of the U.S. economy and the distribution of a COVID-19 vaccine, according to strategists at Goldman Sachs Group. The benchmark S&P 500 has found its footing after plunging 7.45% in the three trading sessions following its Sept. 2 record-high close of 3580.84, amid investor concerns mega-cap technology stocks were becoming too pricy as valuations stretched into the 99.6th percentile, just below those seen at the height of the 2000-2001 dot-com bubble. A correction is marked by a 10% drop from a recent peak. “Despite the sharp sell-off in the past week, we remain optimistic about the path of the US equity market in the coming months,” wrote a Goldman Sachs team led by David Kostin, chief U.S. equity strategist at Goldman Sachs. “The Superforecaster probability of a mass-distributed vaccine by 1Q 2021 has surged to nearly 70% and economic data show a continuing recovery.” Optimism surrounding a potential vaccine provides further support to a U.S. economy that continues to recover following its deepest contraction in the post-World War II era. Goldman Sachs economists said last week that a faster-than-expected snapback in consumer spending will allow the U.S. economy to grow at a 35% pace in the third quarter, up from its previous forecast of 30% growth. They also pinned their forecast on the likelihood a vaccine is succesfully developed. The Wall Street consensus calls for the economy to expand at a 21% annualized rate after contracting by 31.7% in the three months through June amid stay-at-home-orders aimed at slowing the spread of COVID-19. Investors received welcome news on the vaccine front over this past weekend when Pfizer Inc. asked the Food and Drug Administration to expand its late-stage trial to 44,000 participants, up from 30,000. Pfizer CEO Albert Bourla told CBS’ “Face the Nation” on Sunday that a “likely scenario” is that the company’s COVID-19 vaccine will be distributed by the end of the year so long that it is proven to be safe and effective. Johnson & Johnson and Moderna Inc. have experimental vaccines in late-stage trials. AstraZeneca plc and Oxford University announced on Saturday their late-stage trial days had restarted days after it was put on hold due to a participant falling ill. Goldman strategists say a vaccine would be a bullish catalyst for earnings estimates in cyclical sectors, or those most sensitive to a rebounding economy, helping propel the S&P 500 up another 8% from Friday’s close to 3,600 by year-end. They say the five tech stocks, Alphabet Inc., Amazon Inc., Apple Inc., Facebook Inc. and Microsoft Corp., that make up 23% of the S&P 500 are “appropriate” in their weighting due to their growth prospects and strong balance sheets, but are negatively correlated with vaccine probabilities, meaning they could underperform in the event of a discovery. The overhang of the Nov. 3 election remains the biggest source of near-term stock market uncertainty. “Options are pricing a 3% S&P 500 move on November 4 as well as the likelihood of an extended period of uncertainty as mail-in votes are tallied,” the Goldman strategists wrote.

I’ve set records on stock market even amid COVID – Trump

Exactly seven weeks before Election Day and two weeks before the first presidential debate, President Donald Trump faced uncommitted voters in a 90-minute town hall special hosted by ABC News from the battleground state of Pennsylvania.
ABC News Chief Anchor George Stephanopoulos anchored the “20/20” event — “The President and the People” — from the National Constitution Center in Philadelphia. The forum provided uncommitted voters, the opportunity to ask the president their questions on issues affecting Americans from the coronavirus pandemic and economic recovery to protests for racial justice. ABC News offered to host a similar town hall with Democratic presidential nominee and former Vice President Joe Biden, but ABC News and the campaign were not able to find a mutually agreeable date.

US to have COVID-19 vaccine in weeks – Trump

The prospect of a vaccine to shield Americans from coronavirus infection emerged Monday as a point of contention in the White House race as president Donald Trump accused Democrats of “disparaging” for political gain a vaccine he repeatedly has said could be available before the election. “It’s so dangerous for our country, what they say, but the vaccine will be very safe and very effective,” the president pledged at a White House news conference. Trump leveled the accusation a day after Sen. Kamala Harris, the Democrats’ vice presidential candidate, said she “would not trust his word” on getting the vaccine. “I would trust the word of public health experts and scientists, but not Donald Trump,” Harris said. Democratic presidential candidate Joe Biden amplified Harris’ comments Monday after he was asked if he would get a vaccine for COVID-19, the disease caused by the novel coronavirus. Biden said he’d take a vaccine “tomorrow”want to see what the scientists have to say, too. Biden said Trump has said “so many things that aren’t true, I’m worried if we do have a really good vaccine, people are going to be reluctant to take it. So he’s undermining public confidence.” Still, the former vice president said, “If I could get a vaccine tomorrow I’d do it, if it would cost me the election I’d do it. We need a vaccine and we need it now.” The back-and-forth over a coronavirus vaccine played out as three of the candidates fanned out across the country on Labor Day, the traditional start of the two-month sprint to the election. Harris and Vice President Mike Pence campaigned in Wisconsin and Biden went to Pennsylvania. Trump added the news conference to a schedule that originally was blank. Harris, a California Democrat, said in a CNN interview broadcast Sunday that she would not trust a coronavirus vaccine if one were ready at the end of the year because “there’s very little that we can trust that … comes out of Donald Trump’s mouth.” She argued that scientists would be “muzzled” because Trump is focused on getting reelected. Trump dismissed her comments as “reckless anti-vaccine rhetoric” designed to detract from the effort to quickly ready a vaccine for a disease that has killed nearly 190,000 Americans and infected more than 6 million others, according to a count by Johns Hopkins University.

“She’s talking about disparaging a vaccine so that people don’t think the achievement was a great achievement,” Trump said, answering reporters’ questions as he stood at a lectern placed at the front door of the White House on the Pennsylvania Avenue side of the mansion.

“They’ll say anything,” he said. Trump insisted he hasn’t said a vaccine could be ready before November, although he said so repeatedly and as recently as Friday. The president then proceeded to say what he had just denied ever saying. “What I said is by the end of the year, but I think it could even be sooner that that,” he said about a vaccine. “It could be during the month of October, actually could be before November.” Under a program Trump calls “Operation Warp Speed,” the goal is to have 300 million doses of a coronavirus vaccine in stock by January. He has spent hundreds of billions of dollars on what amounts to a huge gamble since vaccine development usually takes years. Concerns exist about political influence over development of a vaccine, and whether one produced under this process will be safe and effective. Dr. Anthony Fauci, the government’s top infectious-disease expert and a member of the White House coronavirus task force, told CNN last week that it is unlikely but “not impossible” that a vaccine could win approval in October, instead of November or December. Fauci added that he’s “pretty sure” a vaccine would not be approved for Americans unless it was both safe and effective.

Stephen Hahn, commissioner of the Food and Drug Administration, has said the agency would not cut corners as it evaluates vaccines, but would aim to expedite its work. He told the Financial Times last week that it might be “appropriate” to approve a vaccine before clinical trials were complete if the benefits outweighed the risks.

White House press secretary Kayleigh McEnany, meanwhile, has given assurances that Trump “will not in any way sacrifice safety” when it comes to a vaccine. And executives of five top pharmaceutical companies pledged that no COVID-19 vaccines or treatments will be approved, even for emergency use, without proof they are safe and effective. Some concerns were sparked by a letter dated Aug. 27 in which Dr. Robert Redfield, director of the Centers for Disease Control and Prevention, asked governors to help government contractor McKesson Corp. make sure vaccine distribution facilities are up and running by Nov. 1. Redfield did not say a vaccine would be ready by then. Three COVID-19 vaccines are undergoing final-stage, or Phase 3, clinical trials in the U.S. Each study is enrolling about 30,000 people who will get two shots, three weeks apart, and then will be monitored for coronavirus infections and side effects for anywhere from a week to two years.

rump Defends Indoor Rally, but Aides Express Concern

WASHINGTON — President Trump and his campaign are defending his right to rally indoors, despite the private unease of aides who called it a game of political Russian roulette and growing concern that such gatherings could prolong the coronavirus pandemic.“I’m on a stage, and it’s very far away,” Mr. Trump said in an interview with The Las Vegas Review-Journal on Monday, after thousands of his supporters gathered on Sunday night inside a manufacturing plant in a Las Vegas suburb, flouting a state directive limiting indoor gatherings to fewer than 50 people. The president did not address health concerns about the rally attendees, a vast majority of whom did not wear masks or practice any social distancing. When it came to his own safety, he said, “I’m not at all concerned.” The decision to hold a rally indoors, officials said, was something of a last resort for a campaign that had tried to procure five different outdoor locations. A Trump campaign official said they all faced pressure from state officials not to host the rally. Xtreme Manufacturing, which finally agreed to host, immediately faced threats from the city of Henderson, Nev. Officials said in a letter made public that the city could charge a fine of $500 for every person over the state’s limit of 50 people and suspend or revoke Xtreme Manufacturing’s business license. Mr. Trump had been defiant during the rally. “If the governor comes after you, which he shouldn’t be doing, I’ll be with you all the way,” he told the crowd. Upcoming Trump rallies in Wisconsin and Minnesota are planned for outdoor airport hangars, the kind of gathering the president recently resumed scheduling with little fanfare but which still violate state guidelines limiting them to fewer than 50 people. But some states like North Carolina, where Mr. Trump held an outdoor rally in Winston-Salem last week, have a First Amendment exemption permitting crowds to gather in the name of freedom of speech. That has led the Trump campaign to distribute signs that read “This is a Peaceful Protest” at its rallies, claiming that attending a rally is an act of political speech. The campaign had no plans to announce any large-scale events that would take place indoors, an official said. But more than 100 people, a majority of them not wearing masks, packed into a hotel ballroom in Arizona for an event on Monday that was billed as a modest round table with the president. Officials said they never considered simply scrapping rallies altogether when their efforts to find an outdoor location failed. For the president, the quiet return of the classic Trumpian political event has been a way to give himself a sense of control during a time when he has little control over events or news cycles. Longtime advisers said they were as important for managing a candidate who needed the cheering crowds to feel energized as they were for energizing the supporters themselves. Still, the return of the rallies was a reversal for the Trump campaign. The president told the radio host Hugh Hewitt last month that he did not plan to hold campaign rallies at all because of concerns about the pandemic. “I’d love to do the rallies. We can’t because of the Covid,” Mr. Trump said. “You know, you can’t have people sitting next to each other.” His critics said the recent rallies in battleground states were more a sign of desperation than of strength. The president is eager to generate news coverage; with 50 days until Election Day, he trails former Vice President Joseph R. Biden Jr., the Democratic candidate, in battleground state polls and his campaign has pulled down ads as its cash advantage has evaporated. Cable channels have cut back on live coverage of Mr. Trump’s rallies, but local affiliates still often carry them in full. Tim Murtaugh, a campaign spokesman, defended the decision to carry on with an indoor rally in the middle of a pandemic. “People are eager to see their president, and our first preference for venues are places like airplane hangars,” he said. “But the fact remains that no one bats an eye at people gambling in casinos or tens of thousands of people protesting shoulder to shoulder. People should be able to gather peacefully under the First Amendment to hear from the president of the United States.” But the decision to forge ahead created a wave of internal backlash, including from a top Trump adviser who said the president was playing a game of Russian roulette in holding the indoor rally. The adviser, who requested anonymity so as not to anger Mr. Trump, said the campaign was taking a cavalier approach to the pandemic that could backfire politically. Some of the president’s most vocal defenders outside of the administration agreed.“Indoor rallies are irresponsible,” Ari Fleischer, a former White House press secretary for President George W. Bush and a frequent defender of Mr. Trump’s, wrote on Twitter.

Eviction filings by big landlords surged after Trump issued ban

Big landlords increased the number of eviction cases they filed after President Donald Trump announced his recent moratorium, signaling the struggle tenants face getting protection from the federal order. Institutional landlords filed more than 900 eviction cases across eight metropolitan areas from Sept. 2 to Sept. 8, according to data compiled by Private Equity Stakeholder Project, an activist group partly funded by organized labor. Landlords filed 165 cases in the same markets during the week of Aug. 3. Fears of an evictions crisis have swirled since expanded unemployment benefits and an original moratorium included in the federal CARES Act expired, with advocates worrying that millions of Americans will lose their homes. The Trump ban, enacted by the Centers for Disease Control and Prevention to avert homelessness during a pandemic, was seen by tenant advocates as a way to delay evictions. But it provides no funding to cover unpaid rent, putting both landlords and tenants at risk and making it difficult to avert a rental crisis. “We’re quite surprised by the number of filings we saw,” Jim Baker, executive director at the Private Equity Shareholder Project, said in an interview. “What’s striking is that we’re not talking about mom-and-pop landlords. We’re talking about gigantic companies.” A wide range of institutional landlords, defined as those that own thousands of units, brought eviction cases during the first week of September. That includes industry giants Starwood Capital Group and Invitation Homes and lesser-known companies like Onni Group, a Vancouver-based developer that manages more than 7,200 apartments. Tenants who complete necessary paperwork should be protected by the moratorium, but that leaves a big hole if they’re not aware of the legal steps required to get protection and very few have lawyers to help. Baker’s organization started compiling eviction data in April to determine whether landlords were complying with the original moratorium, which was limited to buildings with federally backed financing. The research covers 10 large counties covering parts of Atlanta, Houston, Phoenix and five other large metro areas, offering a glimpse into how landlords proceeded in the week after the moratorium was announced on Sept 1. Baker wasn’t expecting to see a jump in evictions because Trump’s new ban goes beyond the old one and applies to all rental buildings. In more than half of the 17 cities tracked by Princeton University’s Eviction Lab, cases filed by landlords of all sizes surged after the CARES Act moratorium effectively expired Aug. 24, said Peter Hepburn, a research fellow for the group. While some building owners may not have been aware of the new tenant protections, others “might have been hoping that they could get under the wire, or that the local courts might take a landlord-friendly approach to enforcement,” Hepburn said. Baker’s research shows eviction cases were still being brought to court Sept. 8, when Invitation Homes, which owns roughly 80,000 single-family rental houses, filed three cases. “We have been doing what the CDC order directs since early in the pandemic – working with our residents facing COVID-related financial hardships and offering a variety of payment options so they can stay in their homes,” the company said in a statement. “As always, we will continue to follow all government directives.” Starwood Capital and Onni Group didn’t respond to requests for comment. The increase in evictions during the first week of September highlights key challenges to implementing the ban, according to John Pollock, coordinator for the National Coalition for a Civil Right to Counsel, an organization that seeks to establish a right to legal representation for defendants in housing court. One problem, he said, is the form tenants have to fill out to get protection, attesting that they’re eligible.“The moratorium is obviously a good thing and it’s going to help people if they know it exists,” he said. “But they have to learn the thing exists, get a copy, fill it out properly and get it to their landlord before the landlord rams an eviction through the court.”

The new coronavirus can infect brain cells, study finds

The coronavirus that causes COVID-19 can sometimes hijack brain cells, using the cells’ internal machinery to copy itself, according to a new study. The research, posted Sept. 8 to the preprint database bioRxiv, has not yet been published in a peer-reviewed journal, but it provides evidence that SARS-CoV-2 can directly infect brain cells called neurons. Although the coronavirus has been linked to various forms of brain damage, from deadly inflammation to brain diseases known as encephalopathies, all of which can cause confusion, brain fog and delirium, there was little evidence of the virus itself invading brain tissue until now. To see whether SARS-CoV-2 could break into brain cells, the study authors examined autopsied brain tissue from three patients who died of COVID-19. They also conducted experiments in mice infected with COVID-19 and in organoids — groups of cells grown in a lab dish to mimic the 3D structure of brain tissue. “This study is the first to do an extensive analysis of SARS-CoV-2 [brain] infection using three models,” said Dr. Maria Nagel, a professor of neurology and ophthalmology at the University of Colorado School of Medicine. In the organoids, the team found that the virus could enter neurons through the ACE2 receptor, a protein on the cell surface that the virus uses to enter the cell and trigger infection. They then used an electron microscope, which uses beams of charged particles to illuminate the tissue, to peer inside infected cells. They could see coronavirus particles “budding” within the cell, demonstrating that the virus had commandeered the neurons’ internal machinery to build new copies of itself. While setting up shop in infected cells, the virus also caused metabolic changes in nearby neurons, which were not infected. These nearby cells died off in large numbers, suggesting that the infected cells might steal oxygen from their neighbors in order to keep producing new virus, the authors noted. in the autopsied tissue, the team found SARS-CoV-2 had infected some neurons in the wrinkled cerebral cortex. Near these infected cells, they found evidence of “small strokes” having taken place, hinting that the virus might steal oxygen from nearby cells in the brain just as it did in the organoids, Iwasaki said. Notably, the infected brain tissue was not flooded with immune cells, as might be expected. So it’s possible that when SARS-CoV-2 manages to infiltrate the brain, it may somehow escape the body’s typical defense against such invasions. It’s not yet known how this unusual immune response might affect the course of the infection, but it may make the virus more difficult to clear from the brain. And though few immune cells flock to the site of infection, dying neurons nearby can trigger a chain-reaction in the nervous system that still leads to harmful inflammation, the authors noted.

Finally, in the mouse experiments, the authors genetically modified one group of mice to express human ACE2 receptors in their brains, while another group of mice only bore the receptor in their lungs. The first set of mice rapidly began losing weight and died within six days, while the second set did not lose weight and survived. In addition, in the mice with brain infection, the arrangement of blood vessels in the brain changed dramatically, presumably to redirect nutrient-rich blood to “metabolically active hot spots” where the virus had taken over, the authors wrote. “Virus may be present in specific brain regions or may have more indirect effects on neurological function,” Nagel added. In particular, some patients experience symptoms reminiscent of chronic fatigue syndrome for months after their initial COVID-19 infection takes hold; it’s been suggested that the syndrome arises from changes in hormone function regulated by the specific parts of the brain, she noted. Another key question is whether the “virus affects the respiratory center in the brainstem — contributing to respiratory failure in critically-ill COVID patients,” she said. When scientists learned that COVID-19 can disrupt people’s ability to smell and taste, some theorized that the virus might infect the brain directly by traveling through nerves in the nose, Live Science previously reported. The virus may invade the brain through the nose, Iwasaki agreed, or it might enter through the bloodstream by crossing compromised regions of the blood-brain barrier — a wall of tissue that normally separates brain tissue from circulating blood and allows only certain substances through. Learning what route the virus takes into the brain will be key to preventing and treating the infection, the authors noted.

Originally published on Live Science.

No comments yet

Biggest Crisis Test Is Still to Come With Insolvencies, BIS Says

(Bloomberg) — Policy makers are facing the most economically challenging part of the Covid-19 crisis in avoiding the creation of “zombie” companies, according to the Bank for International Settlements Ultra-easy monetary and fiscal support is helping companies avoid a liquidity crunch after the pandemic closed down businesses and demand collapsed. But that stance bears risks longer-term, said Claudio Borio, head of the Basel-based institution’s Monetary and Economic Department. “There’s a delicate balance to be struck between on the one hand withdrawing it too early, which will obliviously have short-term costs in terms of economic activity, and withdrawing it too late, which will mean that it will not favor necessary structural adjustments,” he said on Monday. Officials in Europe and the U.S. have unleashed unprecedented easing in response to the Covid-19 outbreak, which has pushed up equity markets even as economies face their deepest recession in decades. While the liquidity measures have helped companies stay afloat, there are concerns they may also be creating a swathe of uncompetitive firms that hold back investment and innovation. “The real challenge is to distinguish between viable and non-viable firms, which, given the uncertainty about future demand patterns, is not straightforward,” Borio said.

Daily US coronavirus cases up by 36,492

  • Covid-19 cases were growing by 5% or more, based on a weekly average to smooth out daily reporting, in 11 states as of Sunday, according to a CNBC analysis of data collected by Johns Hopkins University, an increase from eight states on Friday.
  • The states were Alaska, Arkansas, Connecticut, Delaware, Maine, Nebraska, New Hampshire, New Jersey, Rhode Island, Wisconsin and Wyoming.
  • Wisconsin hit a record high in its average of daily new cases, reporting 1,353 new infections, a roughly 32% increase from a week ago.

Coronavirus cases continued to grow over the weekend in nearly a dozen U.S. states as Dr. Anthony Fauci, the nation’s leading infectious disease expert, warns about the nation’s worrying level of new infections. Covid-19 cases were growing by 5% or more, based on a weekly average to smooth out daily reporting, in 11 states as of Sunday, according to a CNBC analysis of data collected by Johns Hopkins University, an increase from eight states on Friday. The states were Alaska, Arkansas, Connecticut, Delaware, Maine, Nebraska, New Hampshire, New Jersey, Rhode Island, Wisconsin and Wyoming. Wisconsin hit a record high in its average of daily new cases, reporting 1,353 new infections, a roughly 32% increase from a week ago, the Hopkins data shows. Kansas and Montana both hit record highs for new deaths. The new data comes two days after Fauci, director of the National Institute of Allergy and Infectious Diseases, said current data on the U.S. Covid-19 outbreak is “disturbing,” disagreeing with President Donald Trump, who said the U.S. outbreak was “rounding the corner.” While cases are growing in 11 states, the overall daily average of new cases in the U.S. is declining. Over the past seven days, the country has reported an average of about 34,300 new cases per day, down more than 15% compared with a week ago, according to a CNBC analysis of Hopkins data. That’s far lower than the roughly 70,000 new cases a day the U.S. was reporting weeks ago. Still, the 34,300 new cases a day is alarmingly high, infectious disease experts say, and U.S. health officials fear the outbreak could get worse as the nation enters the fall and winter seasons. Health officials have repeatedly warned that they are preparing to battle two bad viruses circulating later this year as the coronavirus outbreak runs into flu season. Earlier this month, Fauci said daily new cases were “unacceptably high” this close to fall. Health officials say the U.S. is unlikely to return to “normal” until there is a safe and effective vaccine. There are currently no U.S.-approved drugs or vaccines for the virus, though U.S. regulators have authorized some treatments for emergency use for hospitalized patients. Earlier in the day, the CEO of Pfizer, one of the frontrunners in the race for a Covid-19 vaccine, said its vaccine could be distributed to Americans before the end of the year if found to be safe and effective. The company is currently in late-stage testing and hopes to enroll up to 44,000 participants. Albert Bourla told CBS’ “Face the Nation” that the drugmaker should have key data from its late-stage trial for the Food and Drug Administration by the end of October. If the FDA approves the vaccine, the company is prepared to distribute “hundreds of thousands of doses,” he said. Even if a vaccine is approved to be distributed before the end of the year, it will likely be in short supply. The vaccine will likely require two doses at varying intervals, and states still face logistical challenges such as setting up distribution sites and acquiring enough needles, syringes and bottles needed for immunizations.

As Trump played down virus, health experts’ alarm grew

WASHINGTON (AP) — Public health officials were already warning Americans about the need to prepare for the coronavirus threat in early February when President Donald Trump called it “deadly stuff” in a private conversation that has only now has come to light. At the time, the virus was mostly a problem in China, with just 11 cases confirmed in the United States. There was uncertainty about how the U.S. ultimately would be affected, and top U.S. officials would deliver some mixed messages along the way. But their overall thrust was to take the thing seriously.“We’re preparing as if this is a pandemic,” Dr. Nancy Messonnier of the Centers for Disease Control and Prevention told reporters on Feb. 5. “This is just good commonsense public health.” Trump, however, had a louder megaphone than his health experts, and in public he was playing down the threat. Three days after delivering his “deadly” assessment in a private call with journalist Bob Woodward, he told a New Hampshire rally on Feb. 10, “It’s going to be fine.” Trump’s acknowledgment in Woodward’s new book “Rage” that he was minimizing the severity of the virus in public to avoid causing panic has triggered waves of criticism that he wasn’t leveling with the American people. The White House has tried to answer that criticism by pointing to selected comments from U.S. health experts to suggest they were on the same page with Trump all along. White House press secretary Kayleigh McEnany highlighted comments from Dr. Anthony Fauci, the nation’s top infectious disease expert, to try to make the case that Trump didn’t lie to the public. She cited a Feb. 17 interview in which Fauci focused his concern on the seasonal flu then playing out. But a day later, Fauci had spoken of alarming potential implications from the new virus, saying, “Not only do we not have an appreciation of the magnitude, even more disturbing is that we don’t have an appreciation of where the magnitude is going.” Mixed safety messages added to confusion. There was considerable discussion about mask-wearing in the early days of the pandemic, with leading experts advising the public against it, saying to leave the masks for health care workers.

“Seriously people — STOP BUYING MASKS!” U.S. Surgeon General Jerome Adams tweeted on Feb. 29. Officials later recommended that people wear face coverings in public and around people who don’t live in their household, based on a review of the latest evidence. “It is irrefutable that he has played down the epidemic and sidelined trusted scientists, and in some cases, muzzled them,” Gostin said. He added: “I categorically deny the idea that there wasn’t a strong consensus of public health experts at the time saying this was a very serious problem.” Trump himself told Woodward on March 19 that he had deliberately minimized the danger. “I wanted to always play it down,” the president said. “I still like playing it down because I don’t want to create a panic.” Critics have long noted how Trump’s public comments failed to sync up with those of public health officials, contributing to confusion among Americans.

Study Shows that Ozone kills Coronavirus

As the coronavirus continues to evolve and become more virulent, there are many unanswered questions as there have been no proper clinical or scientific studies that have been conducted on it yet with regards to its properties etc as the 2019-nCoV coronavirus only made its maiden debut in December 2019. There are questions about how long a virus such as the coronavirus, can survive outside a host ie on surfaces. The influenza virus can survive anything between 5 hours up to 7 days on an outside surface depending on the environment temperature and humidity whereas noroviruses that typically attack the gastrointestinal tract, can survive up to four weeks on surfaces even in hot and dry conditions and can withstand most disinfectants. Typically most respiratory viruses such as the coronavirus favour a cooler temperature. There have been no studies done so far on the new coronavirus or even on the SARS virus, its ‘close cousin’ with regards to how long it can survive outside on surfaces. It is wrong to assume that the coronavirus can only remain active for a few hours on the surface as suggested by one health organization via its online site, that is claiming it’s the leading source of information on the coronavirus when there is no scientific proof of that. In order to be safe, as we still do not really know how long these coronaviruses can survive on surfaces, its best to disinfect areas that have lots of contact with people whether or not they are showing signs of having been infected or not. One good way to do that is by deploying ozone gas.
Ozone gas has been proven to kill the SARS coronavirus and since the structure of the new 2019-nCoV coronavirus is almost identical to that of the SARS coronavirus, it is relatively safe to say that it will also work on the new coronavirus though it must be noted that there are no studies to date except one that is currently ongoing n China at the Institute of Virology In Hubei with regards to this. Progress of that study has shown that it works and the study should be concluded by the end of this week and officially published in the journal Virology. There are more than 17 scientific studies that show Ozone gas is able to destroy the SARS coronavirus.
Ozone is a naturally occurring gas created from oxygen atoms. The oxygen molecule is made up of 2 oxygen atoms. These oxygen molecules are broken into atoms by the corona discharge during lightning storms or by UV light from the Sun. Single oxygen atoms cannot exist alone without regrouping back into diatomic oxygen molecules. During this recombination stage, some atoms will regroup into loosely bonded tri-atomic oxygen. This new molecule is called Ozone or O3. Ozone generators are able to make ozone from normal air and are normally used as room disinfectants.
The antipathogenic effects of ozone have been substantiated for several decades. Its killing action upon bacteria, viruses, fungi, and in many species of protozoa, serve as the basis for its increasing use in disinfecting municipal water supplies in cities worldwide. Typically, viruses are small, independent particles, built of crystals and macromolecules. Unlike bacteria, they multiply only within the host cell. Ozone destroys viruses by diffusing through the protein coat into the nucleic acid core, resulting in damage of the viral RNA. At higher concentrations, ozone destroys the capsid or exterior protein shell by oxidation. Numerous families of viruses including poliovirus I and 2, human rotavirus, Norwalk virus, Parvoviruses, and Hepatitis A, B and non-A non-B are among many others that are susceptible to the virucidal actions of ozone. Most research efforts on ozone’s virucidal effects have centered upon ozone’s propensity to break apart lipid molecules at sites of multiple bond configuration. Indeed, once the lipid envelope of the virus is fragmented, its DNA or RNA core cannot survive. Non-enveloped viruses (Adenoviridae, Picornaviridae, namely poliovirus, Coxsachie, Echovirus, Rhinovirus, Hepatitis A and E, and Reoviridae (Rotavirus), have also begun to be studied. Viruses that do not have an envelope are called “naked viruses.” They are constituted of a nucleic acid core (made of DNA or RNA) and a nucleic acid coat, or capsid, made of protein. Ozone, however, aside from its well-recognized action upon unsaturated lipids, can also interact with certain proteins and their constituents, namely amino acids. Indeed, when ozone comes in contact with capsid proteins, protein hydroxides and protein hydroxides and protein hydroperoxides are formed. Viruses have no protections against oxidative stress. The enveloped viruses are usually more sensitive to physico-chemical challenges than are naked virions. Although ozone’s effects upon unsaturated lipids are one of its best-documented biochemical action, ozone is known to interact with proteins, carbohydrates, and nucleic acids. The new coronavirus is an enveloped virus. Typically ozone generators should only be used by trained personnel as ozone is dangerous to humans. It can destroy your cells lining your mouth, nasal pathways, and your lungs. It has the ability to cause cell mutations and cause cancer. And for those with the underlying disease, brief exposure to it can be dangerous. When using the small ozone generators for small room disinfection, make sure you have a timer and never be in the room when the machine is on. The machine should be operated with windows closed and no living thing in the room including pets for about 10 to 15 minutes. (these small machines have a lower ozone volume output, hence a longer time is preferred.) Do not go into the room for at last 3 hours and upon entering, wear a mask and open all windows and air the place for about 15 minutes first before stepping back in.

References:

Gérard V. Sunnen, SARS and Ozone Therapy: Theoretical Considerations, http://www.triroc.com/sunnen/topics/sars.html (2003)

Ozone therapy: A clinical review
A. M. Elvis and J. S. Ekta
J Nat Sci Biol Med. 2011 Jan-Jun; 2(1): 66–70.
doi: 10.4103/0976-9668.82319

SARS: CLEARING THE AIR
Jerome J. Schentag, Pharm. D., Charles Akers, Ph.D., Pamela Campagna, and Paul Chirayath.
https://www.ncbi.nlm.nih.gov/books/NBK92445/

Development of a Practical Method for Using Ozone Gas as a Virus Decontaminating Agent
James B. Hudson ,Manju Sharma &Selvarani Vimalanathan
Pages 216-223 | Received 30 Jun 2008, Accepted 26 Nov 2008, Published online: 27 May 2009, https://doi.org/10.1080/01919510902747969